Immune checkpoint inhibitors provide durable clinical responses in multiple difficult-to-treat tumor types. The tumor microenvironment, tumor immunogenicity, antigen presentation, and classic ...

Sun Pharma has agreed a takeover deal with US biotech Checkpoint Therapeutics, which recently claimed FDA approval for its first drug but is also running low on cash. The Indian pharma group ...

Cancer patients receiving ICIs may experience more severe toxicity and have a greater risk of death if they have recently used PPIs, data suggest.

Check Point Software Technologies Ltd. engages in the development and market of software and hardware solutions for information technology security. Its ...

Checkpoint Therapeutics’ late entry into the PD-1/PD-L1 inhibitor category, cosibelimab, just got knocked back even further after it was turned down by the FDA as a treatment for skin cancer.